## Click here to access the guidelines/NICE algorithm

	N&WICS - TA764 - Fren	manezumab - Preventing	j migraine		
Before providing patient identifiable parent/legal guardian/carer) has give CSU for processing this funding req	en appropriate explicit consent	for sensitive personal infor	mation on this for		
If there is more than one NICE-approach about the advantages and disadvant patient is likely to adhere to treatme and price per dose) unless an order	ages of the treatments availabent. The most appropriate, leas	ole. This has taken into con st expensive, will be chose	sideration therap	eutic need and wheth	ner or not the
Patient NHS No:	Trust:		Practice Name:		
Patient Hospital No:	Consultant Making Request:		Practice Postcode:		
Patient's Initials and DoB:			Practice Code:		
Notification Email Address:	(@NHS.ne	t account ONLY)	Contact name & number:		
Start date of requested treatment:		e □NHS care □Hospital	Sub-Type:	N/A 🔽	
By completing this form, you confirn commissioning statement. Any requester support regarding IFRs, please For support regarding the criteria lis	ests which fall outside of this u	use will require an individua		•	
Please indicate whether patient meets the following NICE criteria:				Please tick	
Fremanezumab is recommended as an option for preventing migraine in adults, only if:					
• they have 4 or more migraine days a month					
• at least 3 preventive drug treatments have failed and					
the company provides it according to the commercial arrangement.					
2. Stop fremanezumab after 12 w	reeks of treatment if:				
• in episodic migraine (fewer than 15 headache days a month), the frequency does not reduce by at least 50%					
in chronic migraine (15 headach migraine), the frequency does no	•	at least 8 of those having fo	eatures of		
3. As per NICE guidance, treatment the dose required, price per dose	•	•	rug (considering		
Please confirm that the choice of drug is considered the most cost-effective treatment for this individual patient, noting that alternative treatment options recommended by NICE may be lower in cost, including the use of biosimilar medications if applicable.					
Where an alternative lower cost to that the clinical rationale for preson auditing.			•		
4. The product is being used as described by local commissioning position.					
I confirm that the patient meets	s the criteria for treatment				

Name of person completing:	Contact Details:
Designation of person completing:	Date:
Trust Authorising Pharmacist	
Name:  Date:	